Lexaria Achieves Significant Breakthrough in Alternative Nicotine Delivery Technology Kelowna, British Columbia

Lexaria Achieves Significant Breakthrough in Alternative

Nicotine Delivery Technology

Kelowna, British Columbia April 17, 2018 Lexaria Bioscience

Corp. (OTCQX: LXRP) (CSE: LXX) (the Company or Lexaria ), a drug delivery

platform innovator, is pleased to announce positive topline results upon

completion of its first ingestible nicotine in vivo (animal) absorption

study. Lexaria is pursuing the use of its patented DehydraTECHTM

technology as a possible new nicotine delivery method, an edible dose absorbed

through the gastrointestinal tract, with potential both as a nicotine

replacement therapy as well as an alternative product format for regular tobacco

DehydraTECHTM delivered the following major nicotine

absorption performance improvements:

1,160% faster delivery of equivalent peak quantities of nicotine to the

bloodstream than achieved with controls (within 15 min vs. 2.9 hours);

148% gain in the quantity of peak nicotine delivery to the bloodstream

relative to controls;

560% higher brain levels of nicotine where nicotine effects are focused,

compared to controls;

Lower urine levels of nicotine excreted than controls, for enhanced

nicotine activity and bioavailability over the course of the study;

Lower quantities of key liver metabolites in the bloodstream than controls

as hypothesized, suggesting bypass of first pass liver metabolism.

Study Design Parameters:

The study was designed to principally assess the relative

ingestible nicotine absorption performance of DehydraTECHTM-powered

formulations compared to concentration-matched control formulations that lacked

any form of delivery enabling technology in rats. Nicotine was administered in a

nicotine polacrilex derivative format as is widely commercialized today in

nicotine replacement therapy products such as chewing gums. Twelve male rats

were divided into four groups of three, such that DehydraTECHTM and

control formulations were each tested at a 1 mg/Kg and 10 mg/Kg dosage level.

Formulations were administered orally and all rats were cannulated for blood

collection at multiple intervals over an 8 hour duration post-dosing with the

first data collection at the 15-minute mark. Urine and feces were also collected

for up to a 24-hour duration post-dosing, and essential organ tissue samples

were also collected for examination after the study. All samples were subjected

to analytical testing in order to quantify the levels of nicotine therein, as

well as the levels of three major liver metabolites thereof, hydroxycotinine,

nicotine N -oxide and cotinine, in order to assess the relative metabolite levels absorbed by the different formulations. Lexaria's hypothesis was tested to prove that its DehydraTECHTM technology would influence more rapid and complete intestinal bioabsorption of nicotine lymphatically with

less metabolic degradation by the liver. All animals were also assessed for general tolerability of the administered formulations. The study was conducted at the same independent laboratory in Philadelphia where the Company completed its initial

cannabidiol absorption study in 2015.

Results & Observations:

The Lexaria formulations generally achieved faster absorption, higher peak absorption and higher overall quantities of nicotine, on average, in the blood than the concentration-matched control formulations at both the 1mg and 10 mg/Kg doses tested.

Furthermore, as previously reported, there were no obvious signs of gastrointestinal distress such as vomiting or diarrhea indicating that the animals appeared to tolerate the treatment well.

Nicotine blood levels were evaluated multiple times over a period of 8 hours after dosing. In the 10mg/Kg dosing arm, the control formulation required nearly 3 hours to reach similar levels of blood absorption that the Lexaria formulation reached in

only 15 minutes. Furthermore, the Lexaria formulation went on thereafter to demonstrate peak plasma levels that were 148% of those achieved by the control formulation. If replicated in human studies, these findings are suggestive that

Lexaria's technology could prove more effective in elevating blood nicotine levels through edible formats much more quickly and substantially than previously theorized, potentially making ingestible nicotine preparations a viable alternative

to today's available product formats while also leading to a more rapid nicotine craving satiation.

Analysis of the liver metabolites revealed, as expected, that overall levels in the blood of two of the three metabolites studied were higher in the control group than in the Lexaria formulation group at the 10 mg/Kg dose. This result was especially

pronounced in the 45-minute to 2-hour time interval post-dosing which is consistent with the expected timing of release of metabolites in higher quantity into the bloodstream by the liver following normal physiological processing of ingested

nicotine with the control preparation, compared to the DehydraTECHTM technology that is believed to elude first pass liver metabolism. The Lexaria formulation also demonstrated lower quantities of nicotine in the rat urine at both doses,

which is consistent with the fact that the levels of nicotine in the rat blood remained higher over the duration of the study with the Lexaria formulation than with the control. The study also revealed that the Lexaria formulation at the 10 mg/Kg

level achieved up to 5.6 -times as much nicotine upon analysis of the rat brain tissue than was recovered with the matching control formulation. These findings together perhaps suggest prolongation of nicotine effectiveness

with the Lexaria formulation which may also be beneficial in humans to control

cravings over an extended time-period from a single edible nicotine dose.

We are very pleased with these topline study findings

demonstrating excellent tolerability and substantially faster, more potent and

bioavailable absorption of nicotine in an ingestible format with our

DehydraTECHTM technology than controls, said John Docherty,

President. This data supports further investigation of the many possible

benefits of our DehydraTECHTM technology for nicotine delivery with

potential both as a nicotine replacement therapy as well as an alternative

product format for regular tobacco users over today s inhaled options.

Further analysis of the existing data is required, and

additional datasets from the study are still being processed and have not yet

been received by Lexaria. New studies are being planned to pursue investigatory

Lexaria s patented DehydraTECH technology is focused on

improved delivery methodologies of many commonly used active

pharmaceutical ingredient ( API ) substances. As such, it provides an additional

layer of effectiveness that is designed to harmonize with the intellectual

property of third parties. Both patented and generic API substances can utilize

Lexaria s patented technology. Lexaria s long term strategy is to partner with

the world s leading firms as they deliver best-of-class products to their

existing large consumer groups.

Lexaria Bioscience Corp. has developed

and out-licenses its disruptive delivery technology that promotes healthier

ingestion methods, lower overall dosing and higher effectiveness of lipophilic

active molecules. Lexaria has multiple patents pending in over 40 countries

around the world and has patents granted in the USA and in Australia for

utilization of its DehydraTECHTM delivery technology. Lexaria s

technology provides increases in intestinal absorption rates; more rapid

delivery to the bloodstream; and important taste-masking benefits, for orally

administered bioactive molecules including cannabinoids, vitamins, non-steroidal

anti-inflammatory drugs (NSAIDs), nicotine and other molecules. www.lexariabioscience.com

For regular updates, connect with Lexaria on Twitter (https://twitter.com/lexariacorp)

and on Facebook http://tinyurl.com/y8vzcaam

FOR FURTHER INFORMATION PLEASE CONTACT:

Alex Blanchard, Communications Manager

NetworkNewsWire (NNW)

FORWARD-LOOKING STATEMENTS

This release includes forward-looking statements. Statements

which are not historical facts are forward-looking statements. The Company makes

forward-looking public statements concerning its expected future financial

position, results of operations, cash flows, financing plans, business strategy,

products and services, competitive positions, growth opportunities, plans and

objectives of management for future operations, including statements that

include words such as "anticipate," "if," "believe," "plan," "estimate,"

"expect," "intend," "may," "could," "should," "will," and other similar

expressions are forward-looking statements, including but not limited to: that